Shera Hosseini1, Mark Oremus1. 1. 1 School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario.
Abstract
OBJECTIVES: This study was conducted to review the current state of evidence on the association between age of initiation of cannabis use and symptoms of psychosis, depression, or anxiety among youth under 25 years of age. METHODS: We conducted a systematic review of articles published prior to March 2018 by searching OVID MEDLINE, PsycINFO, EMBASE, and the references of included studies. We included comparative studies (cohort, case-control, cross-sectional) that reported on cannabis use in persons <25 years of age (exposure) and symptoms of psychosis, depression, or anxiety (outcome). We narratively synthesized the studies according to design (cohort, etc.) and psychiatric outcome. We used the Newcastle-Ottawa Scale to assess risk of bias. RESULTS: Of the 534 citations identified through the literature search, 23 met the eligibility criteria and were included in this review. With psychosis as the outcome, all except one study found that earlier cannabis use was generally associated with higher risks. With depression/anxiety as the outcome, 6 of the 11 included studies reported findings indicating that earlier use of cannabis was linked to higher symptom levels. CONCLUSION: In persons <25 years old, greater cannabis use is associated with more psychological symptoms, especially among those with a predisposition or existing vulnerability to such outcomes (Oxford Centre for Evidence-Based Medicine level 3 or 4). Policy makers need to consider the adverse effects of cannabis use in youth when planning a public health approach to cannabis legalization.
OBJECTIVES: This study was conducted to review the current state of evidence on the association between age of initiation of cannabis use and symptoms of psychosis, depression, or anxiety among youth under 25 years of age. METHODS: We conducted a systematic review of articles published prior to March 2018 by searching OVID MEDLINE, PsycINFO, EMBASE, and the references of included studies. We included comparative studies (cohort, case-control, cross-sectional) that reported on cannabis use in persons <25 years of age (exposure) and symptoms of psychosis, depression, or anxiety (outcome). We narratively synthesized the studies according to design (cohort, etc.) and psychiatric outcome. We used the Newcastle-Ottawa Scale to assess risk of bias. RESULTS: Of the 534 citations identified through the literature search, 23 met the eligibility criteria and were included in this review. With psychosis as the outcome, all except one study found that earlier cannabis use was generally associated with higher risks. With depression/anxiety as the outcome, 6 of the 11 included studies reported findings indicating that earlier use of cannabis was linked to higher symptom levels. CONCLUSION: In persons <25 years old, greater cannabis use is associated with more psychological symptoms, especially among those with a predisposition or existing vulnerability to such outcomes (Oxford Centre for Evidence-Based Medicine level 3 or 4). Policy makers need to consider the adverse effects of cannabis use in youth when planning a public health approach to cannabis legalization.
Entities:
Keywords:
age at initiation; anxiety; cannabis; depression; psychosis; youth
Authors: Mohammad R Hayatbakhsh; Jake M Najman; Konrad Jamrozik; Abdullah A Mamun; Rosa Alati; William Bor Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-03 Impact factor: 8.829
Authors: Cécile Henquet; Lydia Krabbendam; Janneke Spauwen; Charles Kaplan; Roselind Lieb; Hans-Ulrich Wittchen; Jim van Os Journal: BMJ Date: 2004-12-01
Authors: Krista Lisdahl Medina; Bonnie J Nagel; Ann Park; Tim McQueeny; Susan F Tapert Journal: J Child Psychol Psychiatry Date: 2007-06 Impact factor: 8.982
Authors: Bridget Maloney-Hall; Sarah C Wallingford; Sarah Konefal; Matthew M Young Journal: Health Promot Chronic Dis Prev Can Date: 2020-06 Impact factor: 3.240
Authors: Jessica M Round; Cerina Lee; John G Hanlon; Elaine Hyshka; Jason R B Dyck; Dean T Eurich Journal: BMC Public Health Date: 2020-06-23 Impact factor: 3.295